
Partnering revitalized at the BioFit2022 – in Strasbourg and online
A biologist, a CEO, and a venture capitalist enter the BioFit2022 event...., while this may sound like the beginning of a great joke, it fits the...

Benefits of booster campaigns questionable
While Pfizer Inc and BioNTech SE financial outlooks in February prognosed more than $50bn in combined coronavirus disease (COVID-19) vaccine sales in...

Rewind Therapeutics extends Series A financing
The company, founded by CD3 (Leuven, Belgium) and Axxam S.p.A. (Milan), did not want to reveal the exact amount added to the €15.2m in its 2018...

European Commission calls for reversal of Illumina's $7bn Grail merger
The commission on Monday sent a "statement of objections" outlining the process Illumina must follow in divesting Grail, its blood-testing...

New partnerships push InDevR for Series B financing
Investments into InDevR, Inc. came from New York-based Adjuvant Capital ($4m) and French bioMèrieux SA ($5m), which will enable the commercial...

Germany’s Curevac offers common shares
In addition to these ordinary shares, Tübingen-based CureVac is enticing investors to give up another 15% of the number of ordinary shares under the...

CatalYm GmbH raises €50m to push visugromab development
Following a €60m Series B financing in 2020, Martinsried-based CatalYm GmbH announced the closing of a Series C financing round of €50m. The...